American Journal of Cardiovascular Drugs

, Volume 12, Issue 6, pp 375–389

Olmesartan Medoxomil-Based Antihypertensive Therapy Evaluated by Ambulatory Blood Pressure Monitoring

Efficacy in High-Risk Patient Subgroups
  • Steven G. Chrysant
  • F. Wilford Germino
  • Joel M. Neutel
Review Article

Abstract

Hypertension affects approximately 26% of the world’s adult population and is a recognized major risk factor for morbidity and mortality associated with cardiovascular, cerebrovascular, and renal diseases. However, despite the availability of a range of effective antihypertensive agents and a growing awareness of the consequences of high blood pressure (BP), the treatment and control of hypertension remains sub-optimal. A number of patient subgroups are categorized as ‘high risk’ and may have hypertension that is more difficult to treat, including obese individuals, patients with stage 2 hypertension, those with type 2 diabetes mellitus (T2DM), patients with coronary artery disease or a history of stroke, and Black patients. As the benefits of lowering BP in patients with hypertension are unequivocal, particularly in high-risk patients, treating high-risk patients with hypertension to BP goals and maintaining 24-hour BP control is important to help reduce cardiovascular risk and improve outcomes. Although the BP goals recommended in current consensus guidelines for the management of patients with hypertension are based on cuff BP measurements, ambulatory BP monitoring (ABPM) provides a valuable diagnostic tool and allows a more accurate assessment of BP levels throughout the 24-hour dosing period. ABPM is a better predictor of prognosis than office BP measurement and is also useful for assessing whether antihypertensive therapy remains effective in the critical last few hours of the dosing period, which usually coincides with the morning BP surge associated with arousal and arising.

ABPM has been adopted by new evidence-based guidelines in the United Kingdom to confirm a suspected diagnosis of hypertension, which is an indication of the growing importance of ABPM in the management of hypertension. This review provides an overview of the efficacy and safety of anti-hypertensive therapy based on olmesartan medoxomil ± hydrochlorothiazide and amlodipine/olmesartan medoxomil in high-risk patient populations enrolled in studies that reported ambulatory BP endpoints. The studies identified in this review showed that a titrate-to-BP goal strategy using olmesartan medoxomil- or amlodipine/olmesartan medoxomil-based antihypertensive therapy was an effective and well-tolerated approach for maintaining BP control throughout the full 24-hour dosing period in high-risk patients with difficult-to-treat hypertension.

References

  1. 1.
    Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007 May 29; 115(21): 2761–88PubMedCrossRefGoogle Scholar
  2. 2.
    Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001 Nov 1; 345(18): 1291–7PubMedCrossRefGoogle Scholar
  3. 3.
    Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360(9349): 1903–13PubMedCrossRefGoogle Scholar
  4. 4.
    Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan 15–21; 365(9455): 217–23PubMedGoogle Scholar
  5. 5.
    Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 2010 May 26; 303(20): 2043–50PubMedCrossRefGoogle Scholar
  6. 6.
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289(19): 2560–72PubMedCrossRefGoogle Scholar
  7. 7.
    Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007 Sep; 25(9): 1751–62PubMedCrossRefGoogle Scholar
  8. 8.
    Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009 Nov; 27(11): 2121–58PubMedCrossRefGoogle Scholar
  9. 9.
    American Diabetes Association. Standards of medical care in diabetes — 2012. Diabetes Care 2012 Jan; 35 Suppl 1: S11–63Google Scholar
  10. 10.
    Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011 Mar–Apr; 17 Suppl 2: 1–53PubMedCrossRefGoogle Scholar
  11. 11.
    Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010 Nov; 56(5): 780–800PubMedCrossRefGoogle Scholar
  12. 12.
    Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003 Mar 10; 163(5): 525–41PubMedCrossRefGoogle Scholar
  13. 13.
    Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002 Jan; 25(1): 134–47PubMedCrossRefGoogle Scholar
  14. 14.
    Pessina AC. Target organs of individuals with diabetes caught between arterial stiffness and damage to the microcirculation. J Hypertens Suppl 2007 Jun; 25(1): S13–8PubMedCrossRefGoogle Scholar
  15. 15.
    American Diabetes Association. Standards of medical care in diabetes — 2009. Diabetes Care 2009 Jan; 32 Suppl 1: S13–61CrossRefGoogle Scholar
  16. 16.
    Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics — 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009 Jan 27; 119(3): e21–181PubMedCrossRefGoogle Scholar
  17. 17.
    Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics — 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008 Jan 29; 117(4): e25–146PubMedCrossRefGoogle Scholar
  18. 18.
    National Institute for Health and Clinical Excellence. Hypertension: the clinical management of primary hypertension in adults. Clinical Guideline 127, Methods, evidence, and recommendations, August 2011: National Institute for Health and Clinical Excellence (NICE); 2011 [online]. Available from http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf [Accessed 2011 Dec 14]
  19. 19.
    Pickering TG, White WB. ASH position paper: when and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2008 May–Jun; 2(3): 119–24PubMedCrossRefGoogle Scholar
  20. 20.
    Frohlich ED. Blood pressure measurement. Can J Cardiol 1995 Nov; 11 Suppl. H: 35H–7HPubMedGoogle Scholar
  21. 21.
    Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003 Jun 12; 348(24): 2407–15PubMedCrossRefGoogle Scholar
  22. 22.
    Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans. A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005 Feb 8; 111(5): 697–716PubMedCrossRefGoogle Scholar
  23. 23.
    Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension 2000 Mar; 35(3): 844–51PubMedCrossRefGoogle Scholar
  24. 24.
    Burr ML, Dolan E, O’Brien EW, et al. The value of ambulatory blood pressure in older adults: the Dublin outcome study. Age Ageing 2008 Mar; 37(2): 201–6PubMedCrossRefGoogle Scholar
  25. 25.
    White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001 Apr; 6(2): 63–72PubMedCrossRefGoogle Scholar
  26. 26.
    Gosse P, Lasserre R, Minifie C, et al. Blood pressure surge on rising. J Hypertens 2004 Jun; 22(6): 1113–8PubMedCrossRefGoogle Scholar
  27. 27.
    Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989 Apr; 79(4): 733–43PubMedCrossRefGoogle Scholar
  28. 28.
    Pickering TG, Kario K. Nocturnal non-dipping: what does it augur? Curr Opin Nephrol Hypertens 2001 Sep; 10(5): 611–6PubMedCrossRefGoogle Scholar
  29. 29.
    Routledge F, McFetridge-Durdle J. Nondipping blood pressure patterns among individuals with essential hypertension: a review of the literature. Eur J Cardiovasc Nurs 2007 Mar; 6(1): 9–26PubMedCrossRefGoogle Scholar
  30. 30.
    O’Brien E, Asmar R, Beilin L, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005 Apr; 23(4): 697–701PubMedCrossRefGoogle Scholar
  31. 31.
    Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006 Jun 1; 354(22): 2368–74PubMedCrossRefGoogle Scholar
  32. 32.
    Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet 2011 Oct 1; 378(9798): 1219–30PubMedCrossRefGoogle Scholar
  33. 33.
    Kjeldsen SE, Os I, Hoieggen A, et al. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005; 5(1): 17–22PubMedCrossRefGoogle Scholar
  34. 34.
    Chrysant SG, Izzo JL Jr, Kereiakes DJ, et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a sub-population analysis of the TRINITY study. J Am Soc Hypertens 2012 Mar–Apr; 6(2): 132–41PubMedCrossRefGoogle Scholar
  35. 35.
    Kereiakes DJ, Neutel J, Stoakes KA, et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. J Clin Hypertens (Greenwich) 2009 Aug; 11(8): 411–21CrossRefGoogle Scholar
  36. 36.
    Neutel JM, Kereiakes DJ, Waverczak WF, et al. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin 2010 Mar; 26(3): 721–8PubMedCrossRefGoogle Scholar
  37. 37.
    Fogari R, Taddei S, Holm-Bentzen M, et al. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study. Clin Drug Investig 2010; 30(9): 581–97PubMedCrossRefGoogle Scholar
  38. 38.
    Izzo Jr JL, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich) 2007 Jan; 9(1): 36–44CrossRefGoogle Scholar
  39. 39.
    Oparil S, Pimenta E. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex. J Clin Hypertens (Greenwich) 2010 Jan; 12(1): 3–13CrossRefGoogle Scholar
  40. 40.
    Kereiakes DJ, Chrysant SG, Izzo Jr JL, et al. Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. J Clin Hypertens 2012 Mar; 14(3): 149–57CrossRefGoogle Scholar
  41. 41.
    Nakayama S, Watada H, Mita T, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008 Jan; 31(1): 7–13PubMedCrossRefGoogle Scholar
  42. 42.
    White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011 Mar; 57(3): 413–20PubMedCrossRefGoogle Scholar
  43. 43.
    Punzi H, Neutel JM, Kereiakes DJ, et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis 2010 Aug; 4(4): 209–21PubMedCrossRefGoogle Scholar
  44. 44.
    Punzi H, Shojaee A, Waverczak WF, et al. Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. J Clin Hypertens (Greenwich) 2011 Jun; 13(6): 422–30CrossRefGoogle Scholar
  45. 45.
    Weir MR, Hsueh WA, Nesbitt SD, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/− hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011 Jun; 13(6): 404–12CrossRefGoogle Scholar
  46. 46.
    Hsueh WA, Shojaee A, Maa J-F, et al. Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy. Curr Med Res Opin. Epub. DOI: 10.1185/03007995. 2012.740632Google Scholar
  47. 47.
    Neutel J, Kereiakes DJ, Stoakes KA, et al. Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age >/=65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration study. Drugs Aging 2011 Jun 1; 28(6): 477–90PubMedCrossRefGoogle Scholar
  48. 48.
    Germino FW, Neutel JM, Dubiel R, et al. Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension. Am J Cardiovasc Drugs 2012 Oct; 12(5): 325–33PubMedGoogle Scholar
  49. 49.
    Kereiakes DJ, Neutel J. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring. Ther Adv Cardiovasc Dis 2010 Oct; 4(5): 285–93PubMedCrossRefGoogle Scholar
  50. 50.
    Neutel JM, Kereiakes DJ. An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study. Am J Cardiovasc Drugs 2010; 10(5): 289–303PubMedCrossRefGoogle Scholar
  51. 51.
    Ram CV, Sachson R, Littlejohn T, et al. Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. Am J Cardiol 2011 May 1; 107(9): 1346–52PubMedCrossRefGoogle Scholar
  52. 52.
    Tofé Povedano S, Garcia De La Villa B. 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J Clin Hypertens (Greenwich) 2009 Aug; 11(8): 426–31CrossRefGoogle Scholar
  53. 53.
    Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig 2009; 29(6): 381–91PubMedCrossRefGoogle Scholar
  54. 54.
    Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) 2009 Sep; 11(9): 475–82CrossRefGoogle Scholar
  55. 55.
    Ichikawa S, Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res 2001 Nov; 24(6): 641–6PubMedCrossRefGoogle Scholar
  56. 56.
    Oparil S, Chrysant SG, Melino M, et al. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil +/− hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial. J Hum Hypertens 2010 Dec; 24(12): 831–8PubMedCrossRefGoogle Scholar
  57. 57.
    Kereiakes DJ, Izzo J, Chrysant S, et al. The long-term safety and tolerability of combination olmesartan medoxomil/amlodipine besylate+hydrochlorothiazide in patients with hypertension: the TRINITY study [abstract]. 23rd Scientific Meeting of the International Society of Hypertension (ISH); 26 Sep 2010; Vancouver; 2010; A1994Google Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Steven G. Chrysant
    • 1
  • F. Wilford Germino
    • 2
  • Joel M. Neutel
    • 3
  1. 1.Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of MedicineOklahoma CityUSA
  2. 2.Department of Internal MedicineOrland Primary Care SpecialistsOrland ParkUSA
  3. 3.Orange County Research CenterTustinUSA
  4. 4.Oklahoma Cardiovascular and Hypertension CenterOklahoma CityUSA

Personalised recommendations